Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

8MW 0511

Drug Profile

8MW 0511

Alternative Names: 8MW-0511; MW-05; Recombinant (yeast secreted) human serum albumin-human granulocyte colony stimulating factor (I) fusion protein - Mabwell (Shanghai) Bioscience

Latest Information Update: 21 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mabwell (Shanghai) Bioscience
  • Class Albumins; Granulocyte colony-stimulating factors; Recombinant fusion proteins
  • Mechanism of Action Granulocyte colony-stimulating factor replacements; Haematopoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Neutropenia

Most Recent Events

  • 19 Dec 2023 Preregistration for Neutropenia (Prevention, Chemotherapy-induced) in China (SC)
  • 23 Oct 2023 Mabwell (Shanghai) Bioscience announces intention to submit NDA for Neutropenia in 2023
  • 20 Oct 2023 Efficacy and adverse events data from the phase II trial in Gastric cancer presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top